Hardev S Pandha - JoVE Visualize

Showing results (61-70 of 63) with videos related to

Pageof 7

Sort By:

You have reached the last page of results.This site can display upto 63 results.

The New England Journal of Medicine|October 11, 2016

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyAlain Ravaud, Robert J Motzer, Hardev S Pandha, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factorJennifer C C Hu, Robert S Coffin, Ceri J Davis, et al.

Journal for Immunotherapy of Cancer|January 20, 2023

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.

Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:

Pageof 7

You have reached the last page of results.This site can display upto 63 results.

The New England Journal of Medicine|October 11, 2016

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyAlain Ravaud, Robert J Motzer, Hardev S Pandha, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factorJennifer C C Hu, Robert S Coffin, Ceri J Davis, et al.

Journal for Immunotherapy of Cancer|January 20, 2023

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.

Pageof 7